sb 203580 has been researched along with quazinone in 1 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (quazinone) | Trials (quazinone) | Recent Studies (post-2010) (quazinone) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 42 | 2 | 13 |
| Protein | Taxonomy | sb 203580 (IC50) | quazinone (IC50) |
|---|---|---|---|
| cGMP-inhibited 3',5'-cyclic phosphodiesterase B | Homo sapiens (human) | 0.24 | |
| cGMP-inhibited 3',5'-cyclic phosphodiesterase A | Homo sapiens (human) | 0.24 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Horiuchi, M; Mita, S; Oki, K; Senda, T; Tsuji, F | 1 |
1 other study(ies) available for sb 203580 and quazinone
| Article | Year |
|---|---|
Effects of mitogen-activated protein kinase inhibitors or phosphodiesterase inhibitors on interleukin-1-induced cytokines production in synovium-derived cells.
Topics: 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone; Calcium-Calmodulin-Dependent Protein Kinases; Cytokines; Dose-Response Relationship, Drug; Humans; Imidazoles; Interleukin-1; Phosphodiesterase Inhibitors; Pyridines; Pyrrolidinones; Quinazolines; Rolipram; Synovial Membrane | 1999 |